SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin 2004; 54: 829.
  • 2
    Balch CM, Soong SJ, Gershenwald J, et al. Prognostic factors analysis of 17,600 melanoma patients: validation of the AJCC melanoma staging system. J Clin Oncol 2001; 19: 36223634.
  • 3
    Balch CM, Buzaid AC, Atkins MB, et al. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 2000; 88: 14841491.
  • 4
    Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001; 19: 36353648.
  • 5
    Balch CM. Cutaneous Melanoma, in GreeneFL, PageDL, FlemingID, et al. (eds). AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer Verlag; 2002: 209217.
  • 6
    Merkel S, Meyer T, Papadopoulos T, et al. Testing a new staging system for cutaneous melanoma proposed by the American Joint Committee on Cancer. Eur J Cancer 2002; 38: 517526.
  • 7
    Retsas S, Henry K, Mohammed MQ, MacRae K. Prognostic factors of cutaneous melanoma and a new staging system proposed by the American Joint Committee on Cancer (AJCC): validation in a cohort of 1284 patients. Eur J Cancer 2002; 38: 511516.
  • 8
    Kashani-Sabet M, Shaikh L, Miller JR III, et al. NF-kappa B in the vascular progression of melanoma. J Clin Oncol 2004; 22: 617623.
  • 9
    Garbe C, Ellwanger U, Tronnier M, et al. The New American Joint Committee on Cancer staging system for cutaneous melanoma: a critical analysis based on data of the German Central Malignant Melanoma Registry. Cancer 2002; 94: 23052307.
  • 10
    Averbook BJ, Fu P, Rao JS, Mansour EG. A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: implications on the future of cancer staging. Surgery 2002; 132: 589602; discussion 602–604.
  • 11
    Essner R, Conforti A, Kelley MC, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999; 6: 442449.
  • 12
    Morton DL, Wen DR, Wong JH, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392399.
  • 13
    Breslow A. Problems in the measurement of tumor thickness and level of invasion in cutaneous melanoma. Hum Pathol 1977; 8: 12.
  • 14
    Breslow A. Thickness, cross-sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970; 172: 902908.
  • 15
    Balch CM, Murad TM, Soong SJ, et al. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 1978; 188: 732742.
  • 16
    Balch CM, Wilkerson JA, Murad TM, et al. The prognostic significance of ulceration of cutaneous melanoma. Cancer 1980; 45: 30123017.
  • 17
    Clark WH, Jr, From L, Bernardino EA, Mihm MC. The histogenesis and biologic behavior of primary human malignant melanomas of the skin. Cancer Res 1969; 29: 705727.
  • 18
    Buzaid AC, Ross MI, Balch CM, et al. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system [see comments]. J Clin Oncol 1997; 15: 10391051.
  • 19
    Lock-Andersen J, Hou-Jensen K, Hansen JP, et al. Observer variation in histological classification of cutaneous malignant melanoma. Scand J Plast Reconstr Surg Hand Surg 1995; 29: 141148.
  • 20
    Morton DL, Davtyan DG, Wanek LA, et al. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993; 71: 37373743.
  • 21
    Marghoob AA, Koenig K, Bittencourt FV, et al. Breslow thickness and Clark level in melanoma: support for including level in pathology reports and in American Joint Committee on Cancer Staging [see comments]. Cancer 2000; 88: 589595.
  • 22
    McKinnon J, Yu XQ, McCarthy WH, Thompson JF. Prognosis for patients with thin cutaneous melanoma: long-term survival data from New South Wales Central Cancer Registry and the Sydney Melanoma Unit. Cancer 2003; 98: 12231231.
  • 23
    Gershenwald JE, Balch CM, Soong SJ, Thompson JF. Prognostic Factors and Natural History, in BalchCM, HoughtonAN, SoberAJ, et al. (eds). Cutaneous Melanoma. 4th ed. St. Louis, MO: Quality Medical Publishing; 2003: 2554.
  • 24
    Balch CM, Gershenwald JE, Buzaid AC, et al. Staging and Classification, in BalchCM, HoughtonAN, SoberAJ, et al. (eds). Cutaneous Melanoma. 4th ed. St. Louis, MO: Quality Medical Publishing; 2003: 5592.
  • 25
    Balch CM, Soong S, Ross MI, et al. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7: 8797.
  • 26
    Cascinelli N, Belli F, Santinami M, et al. Sentinel lymph node biopsy in cutaneous melanoma: the WHO Melanoma Program experience. Ann Surg Oncol 2000; 7: 469474.
  • 27
    Buzaid AC, Tinoco LA, Jendiroba D, et al. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 1995; 13: 23612368.
  • 28
    Cascinelli N, Bufalino R, Marolda R, et al. Regional non-nodal metastases of cutaneous melanoma. Eur J Surg Oncol 1986; 12: 175180.
  • 29
    Harrist TJ, Rigel DS, Day CL, Jr, et al. “Microscopic satellites” are more highly associated with regional lymph node metastases than with primary melanoma thickness. Cancer 1984; 53: 21832187.
  • 30
    Barth A, Wanek LA, Morton DL. Prognostic factors in 1,521 melanoma patients with distant metastases. J Am Coll Surg 1995; 181: 193201.
  • 31
    Deichmann M, Benner A, Bock M, et al. S100-Beta, melanoma-inhibiting activity, and lactate dehydrogenase discriminate progressive from nonprogressive American Joint Committee on Cancer stage IV melanoma. J Clin Oncol 1999; 17: 18911896.
  • 32
    Eton O, Legha SS, Moon TE, et al. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 1998; 16: 11031111.
  • 33
    Keilholz U, Conradt C, Legha SS, et al. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol 1998; 16: 29212929.
  • 34
    Sirott MN, Bajorin DF, Wong GY, et al. Prognostic factors in patients with metastatic malignant melanoma. A multivariate analysis. Cancer 1993; 72: 30913098.
  • 35
    Azzola M, Shaw HM, Thompson JF, et al. Tumor mitotic rate is a more powerful prognostic indicator than ulceration in patients with primary cutaneous melanoma. An analysis of 3661 patients from a single center. Cancer 2003; 97: 14881498.
  • 36
    Morton D, Essner R, Balch CM. Surgical Excision of Distant Metastases, in BalchCM, HoughtonAN, SoberAJ, et al. (eds). Cutaneous Melanoma. 4th ed. St. Louis, MO: Quality Medical Publishing; 2003: 547572.